Advanced Therapy Medicinal Products Market Analysis

  • Report ID: 4684
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Advanced Therapy Medicinal Products Market Segmentation:

Disease Segment Analysis

The dermatology segment is to garner the highest advanced therapy medicinal products market revenue at the end of 2035. The segment growth is expected on the back of rising cases of skin problems and cancer in the world. According to the World Health Organization, currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually worldwide. Skin cancer accounts for one in three cancer diagnoses, and one in five Americans will have it at some point in their lives.

Product Segment Analysis

The gene therapy segment is expected to grow at healthy CAGR over the forecast period. The segment growth is expected on the back of a higher number of people in need of gene therapy and growing clinical trials of gene therapy. By 2035, gene therapies could be used to treat more than 1 million Americans. Furthermore, in 2022, around 1221 cell and gene therapies are under active clinical trials, moreover, out of them nearly 324 clinical trials are in the phase of 1/1b.

Our in-depth analysis of the global market includes the following segments:

          By Product

  • CAR-T Therapy
  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered Product

               By Disease

  • Oncology
  • Genetic Disorder
  • CNS
  • Dermatology
  • Others

                By End User

  • Hospitals & Clinics
  • Research & Academic Institutes

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.

The global advanced therapy medicinal products market size was valued at over USD 45.2 billion in 2025 and is expected to expand at a CAGR of over 14.5%, surpassing USD 175.06 billion revenue by 2035.

North America advanced therapy medicinal products market is predicted to capture 44% share by 2035, driven by higher cases of cancer and neurological disorders and private investment.

Key players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos